Seeking Alpha

Acorda Therapeutics (ACOR +15.4%) says a European Medicine Agency committee has recommended...

Acorda Therapeutics (ACOR +15.4%) says a European Medicine Agency committee has recommended marketing approval for its multiple-sclerosis pill Fampyra, a drug that aims to improve walking in MS patients. Acorda developed the drug, and Biogen (BIIB +0.8%) is developing and marketing it outside the U.S. under a licensing agreement from Acorda. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|